COVID-19

CVS is the first pharmacy to offer this service nationwide.

With closing remarks, Mitchel Rothholz, RPh, MBA, and Jeff Goad, PharmD, MPH, discuss common myths circulating around COVID-19 vaccines and vaccination.

Expert panelists highlight special considerations when selecting COVID-19 vaccines.

A real-world study determined the efficacy of mRNA vaccines for protection against COVID-19 in adolescents.

Although initial infection of the virus has resulted in risk of hospitalization and mortality, researchers looked into the effects of reinfection as data has been unclear.

Compared to the original mRNA-1273 booster dose, the bivalent booster mRNA -1273.222 was superior against Omicron variants.

Communication and education are critical to patient confidence in emergency use authorization vaccines.

Mitchel Rothholz, RPh, MBA, and Jeff Goad, PharmD, MPH, share thoughts on COVID-19 vaccines and boosters in anticipation of an uptick in cases in the coming months.

Key opinion leaders share insights regarding considerations for COVID-19 boosters amid variants.

Addressing hesitancy is more than just offering pertinent information.

Experts discuss comorbidities as risk factors for patients developing severe COVID-19 symptoms.

Medical experts discuss potential long-term adverse effects associated with COVID-19.

Drs Rothholz and Goad discuss population health strategies for COVID-19.

Pharmacists play a significant role in patient education regarding COVID-19 vaccines.

Mitchel Rothholz, RPh, MBA, and Jeff Goad, PharmD, MPH, share insights regarding COVID-19 potentially achieving endemic status.

COVID-19 bivalent booster uptake has been very sluggish, even though the booster provides better protection against newer variants. What can pharmacists and their teams do to improve booster rates?

Findings by researchers at Epic, the electronic health record company, show that the benefits extend to people ages 50-64.

Although few cultures showed bacterial coinfections, many children were given antibiotics.

Additional research is needed to fully understand the scope of Long COVID.

Moderna’s bivalent mRNA COVID-19 booster reached prespecified superiority and noninferiority criteria against multiple strains of SARS-CoV-2.

The Omicron variant radically changed reinfection rates.

A selection of the latest COVID-19 vaccine research out of IDWeek 2022.

Adults who receive influenza and pneumococcal vaccines may be more likely to receive COVID-19 vaccines and boosters.

The authorization offers another COVID-19 booster choice for adults.